Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

LEUVEN, Belgium, August 27 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

During 2009, ThromboGenics has continued to focus on the activities which are key to its aim of becoming a profitable, integrated company focused on cutting edge ophthalmic medicines. Central to this plan is the Company's lead product, microplasmin, which is in Phase III trials for the treatment of back of the eye disease. Patient recruitment in this Phase III program is running smoothly and the Company expects to report the first results from these studies by mid 2010.

The clinical development of the Company's unique long-acting anticoagulant TB-402, which is in Phase II trials for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery, has progressed more rapidly than originally expected.

Patrik De Haes, CEO of ThromboGenics, said:

"ThromboGenics has seen most of its key programs make significant progress during the course of 2009. We are very happy with the speed of patient recruitment in the microplasmin Phase III program. Microplasmin is central to our aim of building a strong, profitable and integrated company centered on cutting edge ophthalmic medicines. Given our increasing confidence in the clinical merits of microplasmin we are now starting to develop our commercialization plans for this novel product. We are also very encouraged by the progress of the Phase II program for TB-402, as recruitment is ahead of schedule. This clinical study has reinforced our view that we have an attractive out-licensing opportunity for companies keen to enhance their position in the anti-coagulant therapy market. Our partnership with
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 For the past five ... the auspices of the Armed Forces Institute of ... academic research organizations in the development of advanced ... is a multi-institutional, inter¬disciplinary network working to develop ... suffered by US servicemen and women in the ...
(Date:8/1/2014)... the photonic analog of topological electron flow in certain ... around the edge of the material but not through ... if electrons encounter impurities in the material the electrons ... In the photonic equivalent, light flows ... a meta-material consisting of an array of tiny glass ...
(Date:8/1/2014)... Chantel Lee ’15 and Eli Capello ’15 sacrificed a leisurely ... Juan Rodriguez, Professor of Physics, in an effort to combat ... caused by changes in the blood vessels of the retina. ... remarkable,” said Rodriguez. “They took on a graduate level project, ... carried it to near completion in just a few short ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Applied ... provider of DNA-based anti-counterfeiting technology and product authentication solutions, ... 2014 to discuss its fiscal third quarter results. The ... the SEC by the end of the day on ... Inc. management will host a conference call beginning at ...
Breaking Biology Technology:Wounded Warriors a Focus of the 12th New Jersey Symposium on Biomaterials Science 2On-chip topological light 2On-chip topological light 3Two Centenary College Students Tackle Diabetic Retinopathy Research 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3
... a private,biotechnology company and leading developer of clean ... Singapore,Pte. Ltd. (CLS). CLS is the company,s first ... the company,s research and development operations in the,U.S. ... business in,both the innovator and generics markets. ...
... Inc. (Amex: PLX ), announced today the pricing ... common stock at a,public offering price of $5.00 per ... underwriters to purchase up to 1,500,000 additional shares of,common ... Bank is acting as sole book-running manager for this,offering. ...
... Inc. (Nasdaq: HGSI ) today announced that it ... for the quarter ended,September 30, 2007. These results are ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) The conference call will ... Thursday, November 1, 2007, at 11:00 am Eastern Time. ...
Cached Biology Technology:Codexis Opens Singapore Laboratory 2Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock 2Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results 2
(Date:8/1/2014)... As a quantum state collapses from a quantum superposition to ... a path known as a quantum trajectory. For each start ... path, but it is not as easy to predict the ... points would be in our everyday, classical world. , In ... Nature , scientists from the Institute for Quantum Studies ...
(Date:8/1/2014)... reptile species have been recorded into the Reptile ... species and classification, making the reptile species among ... alongside bird and fish species. , For some ... the year that reptiles would become the most ... snakes, lizards, turtles, crocodiles, tuataras and amphisbaenians. , ...
(Date:8/1/2014)... fossil record about 200,000 years ago, but it was ... advanced tools became widespread. , A new study ... finds that human skulls changed in ways that ... same time that culture was blossoming. , "The modern ... cultural exchange probably came at the same time that ...
Breaking Biology News(10 mins):Mapping the optimal route between two quantum states 2Reptile Database surpasses 10,000 reptile species 2Reptile Database surpasses 10,000 reptile species 3Society bloomed with gentler personalities and more feminine faces 2
... Without aggressive action to reduce soot emissions, the time ... be significantly accelerated in order to achieve international climate ... December,s Copenhagen Accord, according to " Assessing the climatic ... online June 21 in the Proceedings of the National ...
... product is organic, it,s also environmentally friendly. ... organic pesticides can have a higher environmental impact ... require larger doses. Environmental sciences professor Rebecca ... effectiveness and environmental impact of organic pesticides to ...
... freshwater fishes has created a great home for parasites, according ... . The study provides a lens into the evolutionary world ... probably has the best studied freshwater fish parasites in the ... more species of flukes in a few fishes from the ...
Cached Biology News:Aggressive action to reduce soot emissions needed to meet climate change goals 2Aggressive action to reduce soot emissions needed to meet climate change goals 3Organic pesticides not always 'greener' choice, study finds 2Adaptation is (not) in the eye of the beholder 2
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... and SYBR Safe DNA Gel Stain combo offers these ... buying these same products separately ... bromide Eliminates risks to ... and RNA fragments from 100 bp to >30 kb. ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... The economical ICS-90 uses continuous chemical ... to give you fast, accurate determinations of ... ranges. Easy to operate, quick to equilibrate, ... the compact ICS-90 helps you achieve maximum ...
Biology Products: